Edwards Lifesciences CFO Scott Ullem to step down by mid-2026

Edwards Lifesciences (EW.N) reported robust third-quarter results, with sales increasing 14.7% to $1.55 billion, surpassing analyst estimates due to strong demand in transcatheter valve therapies. Following these results, the company raised its full-year sales and profit forecasts, driving a 3% gain in after-market trading. Concurrently, CFO Scott Ullem announced his planned departure by mid-2026, transitioning to an advisory role post-succession to ensure continuity during this period of positive momentum.

Analysis

Edwards Lifesciences reported strong third-quarter results, with sales rising 14.7% to $1.55 billion, exceeding LSEG estimates of $1.49 billion. This outperformance was driven by robust demand for its transcatheter valve therapies, leading to a 3% gain in after-market trading.

The company subsequently raised its full-year sales and profit forecasts, reflecting management's confidence in sustained operational momentum and market positioning. This optimistic outlook is supported by the strong underlying fundamentals in its core product categories.

Concurrently, CFO Scott Ullem announced his planned departure by mid-2026, with a transition to an advisory role post-succession. Ullem's tenure since 2014 was marked by significant expansion in structural heart therapies and strategic market shifts, with the extended transition designed to ensure continuity.

Key Decisions for Investors

• Monitor the company's ability to sustain strong demand for transcatheter valve therapies and meet its raised full-year guidance
• Evaluate the strategic implications of the planned CFO transition, including the profile of the successor and potential shifts in financial strategy
• Assess the long-term growth potential from continued expansion into underserved markets, which Ullem helped establish